Field Diagnostics for Pathogen Identification and Surveillance

项目摘要-项目2 大约三分之二的疑似甚高频患者转介到我们在塞拉利昂的甚高频病房 和尼日利亚的拉沙病毒（LASV）或埃博拉病毒（EBOV）感染检测呈阴性。在我们 在临床实践中，我们认为这些患者具有不明原因的发热（FUO）。 下 第二代基因组学分析将用于项目1，以确定微生物的范围。 在三个已建立的VHF临床中心就诊的患者中引起发热性疾病的病原体 穿越西非项目2将扩大这些研究， 设计和验证基于核酸的可现场部署的聚合酶链反应（PCR） 测定和基于重组抗原的免疫测定。在里程碑1中， 技术，并提供培训，以开发和验证外地可部署 定量PCR检测已知和新的病原体，以加强临床护理。转让 开发和验证可现场部署的免疫测定的技术和培训 对于已知和新型病原体，将在 里程碑2.在里程碑3中，我们将进行样本采集、监测和调查， 塞内加尔、塞拉利昂和尼日利亚已知和新病原体的流行病学。的 这些诊断测定的可用性将改善临床护理，并能够增强 监测和调查已知和新型病毒的流行病学，以及其他 微生物病原体导致西非的传染病负担。 1

Project Summary — Project 2 Approximately two-thirds of suspected VHF patients referred to our VHF Wards in Sierra Leone and Nigeria test negative for either Lassa virus (LASV) or Ebola virus (EBOV) infection. In our clinical practices we consider these patients to have a fever of unknown origin (FUO). ​Next generation genomics analyses will be used in Project 1 to define the range of microbial pathogens inducing febrile illnesses in patients presenting to three established VHF clinical sites across West Africa. Project 2 will extend these studies by transferring technical expertise for designing and validating field deployable polymerase chain reaction (PCR) based nucleic acid assays and recombinant antigen based immunoassays. In Milestone 1 we will transfer technology and provide training for the development and validation of field deployable quantitative PCR tests for known and novel pathogens to enhance clinical care. Transfer of technology and training for the development and validation of field deployable immunoassays for known and novel pathogens to allow for rapid diagnosis across many sites will be provided in Milestone 2. In Milestone 3 we will perform sample collection, surveillance and investigation of the epidemiology of known and novel pathogens in Senegal, Sierra Leone and Nigeria. The availability of these diagnostic assays will improve clinical care, and enable enhanced surveillance and investigation of the epidemiology of known and novel viruses, as well as other microbial pathogens contributing to the infectious disease burden in West Africa. 1